IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

Mon, 10th May 2021 11:13

Avacta Group PLC - Yorkshire-based drug and diagnostic equipment developer - Submits declaration of conformity for rapid Covid-19 lateral flow test to the UK's Medicines & Healthcare Products Regulatory Agency. Expects registration of test to be confirmed in the coming days, before it is immediately placed on the market. The test has been shown to be more sensitive than lateral flow tests currently on the market, particularly for lower viral loads.

Current stock price: 266.88 pence, up 1.9% on Monday

Year-to-date change: more than doubled from 114.0p on December 31

By Ivan Edwards; ivanedwards@alliancenews.com

Related Shares

More News

23 May 2024 21:25

TRADING UPDATES: Windward wins deal; Kodal progresses at Bougouni

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

23 May 2024 12:09

Avacta reports further progress in chemotherapy trial

(Sharecast News) - Avacta Group announced the successful completion of the first cohort and the start of dosing for three patients in the second cohor...

7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

1 May 2024 11:53

IN BRIEF: Avacta picks Christina Coughlin to replace long-serving CEO

Avacta Group PLC - Wetherby, West Yorkshire-based life sciences company developing cancer treatments and diagnostics - Promotes Christina Coughlin to ...

30 Apr 2024 16:30

EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down

(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Tuesday and not separately reported by Alliance News: